Tekmira Presents Results of Preclinical Studies With

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Tekmira Presents Results of Preclinical Studies With Hepatitis B Therapeutic

VANCOUVER, British Columbia, Oct. 15, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR ) (TSX: TKM ), a leading developer of RNA interference (RNAi) therapeutics, announced today the presentation of preclinical results characterizing TKM-HBV, a therapeutic agent targeting human hepatitis B virus (HBV), at the 10 th Annual Meeting of the Oligonucleotide Therapeutics Society. Tekmira's Chief Technical Officer, Dr. Ian MacLachlan delivered a podium presentation titled, "Update on the Preclinical Development of an LNP-Based HBV Therapeutic." The conference is taking place in San Diego, California, from October 12 – 15, 2014.

Among the results reported is the potent and rapid reduction in hepatitis B surface antigen (HBsAg) demonstrated by TKM-HBV in several preclinical models including the chronically infected humanized (chimeric) mouse.

"These results reflect the rigorous approach we have taken to the design and characterization of our novel hepatitis B therapeutic," said Dr. Mark J Murray, President and CEO, Tekmira Pharmaceuticals. "TKM-HBV employs a unique combination of three RNAi triggers, in a third generation LNP formulation, which results in broad and effective knockdown of viral mRNAs and viral proteins including hepatitis B surface antigen, our primary therapeutic target. This data supports the utility of TKM-HBV as a new therapeutic option for treating patients with chronic HBV infection. Our plan is to file an IND, or equivalent document, by the end of this year, and initiate clinical trials in early 2015."

Key summary points from the presentation include:

  • Preclinical studies employed several well validated models including true-infection models that support the full viral replication/re-infection cycle and the production of covalently closed circular DNA (cccDNA).
     
  • In these models, TKM-HBV treatment resulted in rapid and potent reductions in both intrahepatic and serum HBsAg, as well as reductions in HBV DNA, cccDNA, HBeAg and HBcAg.
     
  • A rapid 1 log reduction in serum HBsAg was achieved with a single 1 mg/kg dose of TKM-HBV in the chronically infected humanized mouse model, which mimics human hepatitis B infection. 1-2 log viral reductions from similar single-dose LNP treatments in two other true-infection animal models have also been demonstrated.
     
  • Tekmira's data suggests inclusion of three RNAi triggers results in a more broadly effective knockdown of viral products than a single trigger alone.
     
  • By targeting three distinct and highly conserved sites on the HBV genome:
     
    • TKM-HBV is designed to achieve "universal" activity in chronic HBV patients infected with genotypes A through H. Studies conducted on infected primary human hepatocytes showed that TKM-HBV had robust and consistent activity against different viral strains representing the major clinical genotypes A, B, C and D.
       
    • TKM-HBV is designed to achieve a higher threshold against development of antiviral resistance. Preclinical investigation targeting the closely related woodchuck hepatitis virus suggests that the use of a single stand-alone RNAi trigger can result in viral resistance.
       
  • The mode of action of TKM-HBV complements standard of care nucleoside/nucleotide (NUC) therapy, and lack of drug antagonism has been demonstrated with entecavir, lamivudine and tenofovir on infected primary human hepatocytes.
     
  • The drug mechanism of action is well-understood and RNAi-mediated site-specific cleavage of viral mRNA by TKM-HBV has been confirmed using RLM-RACE sequence analysis.

A copy of Tekmira's presentation from the 10 th Annual Meeting of the Oligonucleotide Therapeutics Society Meeting will be available on the Tekmira website on the "Events" section at: http://investor.tekmirapharm.com/events.cfm

About RNAi and Tekmira's LNP

RNAi therapeutics have the potential to treat a number of human diseases by "silencing" disease causing genes. The discoverers of RNAi, a gene silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi trigger molecules often require delivery technology to be effective as therapeutics. Tekmira believes its LNP technology represents the most advanced and widely adopted delivery technology for the systemic delivery of RNAi triggers. Tekmira's LNP platform is being utilized in multiple clinical trials in various disease areas by Tekmira and its partners. Tekmira's LNP technology (formerly referred to as stable nucleic acid-lipid particles or SNALP) encapsulates RNAi triggers with high efficiency in uniform lipid nanoparticles that are effective in delivering these therapeutic compounds to disease sites. Tekmira's LNP formulations are manufactured by a proprietary method which is robust, scalable and highly reproducible, and LNP-based products have been reviewed by multiple regulatory agencies for use in clinical trials. LNP formulations comprise several lipid components that can be adjusted to suit the specific application.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle (LNP) delivery technology to pharmaceutical and biotechnology partners. Tekmira has been working in the field of nucleic acid delivery for over a decade, and has broad intellectual property covering its delivery technology. Further information about Tekmira can be found at www.tekmira.com . Tekmira is based in Vancouver, Canada and Seattle, USA.

About TKM-HBV

TKM-HBV is designed to eliminate hepatitis B surface antigen expression in chronically infected patients. Blocking HBV surface antigen – and reducing the pathology associated with its expression may enable patients to raise antibody against the virus. The ability of TKM-HBV to collectively reduce several viral elements in addition to surface antigen, allows effective targeting of the hepatitis B virus at multiple critical nodes in the infection cycle. 

TKM-HBV is being developed as a multi-component RNAi therapeutic that simultaneously targets three sites on the HBV genome. Because HBV is a viral infection of the liver, TKM-HBV will employ a liver-centric LNP formulation that is more potent than any LNP currently in clinical development.

About HBV

The hepatitis B virus (HBV) is a DNA virus belonging to the Hepadnaviridae family of viruses. Approximately 350 million individuals in the world and one million in the United States are chronically infected with HBV, many of whom appear healthy but can spread the virus to others. Chronic hepatitis B may lead to cirrhosis, liver cancer or liver failure. Approximately 15% to 25% of people with chronic infection will die prematurely as a result of the infection, and the disease typically progresses gradually over the course of several decades. Current treatments are able to suppress HBV if taken indefinitely, but these do not typically lead to a functional cure, and viral rebound is observed upon treatment stoppage. ( www.medicinenet.com/hepatitis_b )

Forward-Looking Statements and Information

This news release contains "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking statements"). Forward-looking statements in this news release include statements about Tekmira's strategy, future operations, clinical trials, prospects and the plans of management; the results reported by Tekmira on TKM-HBV in preclinical models; plans to file an IND, or equivalent document, by the end of this year and initiate clinical trials in early 2015 for TKM-HBV; the effects and potency of Tekmira's product TKM-HBV on chronic Hepatitis B infection; and estimations of unmet demands for TKM-HBV. 

With respect to the forward-looking statements contained in this news release, Tekmira has made numerous assumptions regarding, among other things: LNP's status as a leading RNAi delivery technology; the effectiveness of RNAi therapeutics in the treatment of Hepatitis B virus; and the results of true-infection animal models. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause Tekmira's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: RNAi based therapeutics may not prove to be effective in the treatment of Hepatitis B virus as currently anticipated, compared to other therapeutics, or at all; Tekmira may not file an IND, or equivalent document, or initiate clinical trials for TKM-HBV as currently anticipated, or at all; the FDA or other regulatory agencies may refuse to approve Tekmira's products, or place restrictions on Tekmira's ability to commercialize its products; anticipated pre-clinical and clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; future operating results are uncertain and likely to fluctuate; economic and capital market conditions; and the possibility that Tekmira may not have sufficiently budgeted for expenditures necessary to carry out planned activities.

A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira's Annual Report on Form 10-K and Tekmira's continuous disclosure filings, which are available at www.sedar.com and www.sec.gov . All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Tekmira disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Investors Julie P. Rezler Director, Investor Relations Phone: 604-419-3200 Email: Media Please direct all media inquiries to

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 75

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 102

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 80

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 112

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 22

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 64

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 11

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 71

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading

Top 5 Most Recently Viewed Articles

TriPost Partners with Brixton Capital for Retail Expansion

Updated Category News Views 254

Strategic Partnership between TriPost and Brixton Capital TriPost Capital Partners, a real estate private equity firm, is thrilled to announce a significant partnership with Brixton Capital for acquiring a grocery-anchored retail portfolio. This collaboration focuses on high-quality investment opportunities in rapidly developing markets. Details of the Portfolio...

Continue Reading
Archer Aviation: Pioneering A New Era in Defense Technology

Updated Category News Views 200

Archer Aviation: A New Vision for Military Transportation When considering groundbreaking advancements in transportation, one might think of popular electric cars, but now there's a fresh contender: Archer Aviation Inc. This company stands out in the realm of electric vertical takeoff and landing aircraft (eVTOL), showcasing a vision that aligns with modern defense needs....

Continue Reading
Understanding Civil Claims for Rideshare Sexual Assault Victims

Updated Category News Views 279

Understanding Civil Claims for Rideshare Sexual Assault Victims Victims of sexual assault during rideshare trips have avenues to seek justice and compensation. With cases involving rideshare companies like Uber and Lyft, survivors might find themselves facing challenging circumstances after an assault. Fortunately, there are legal options available for those affected by...

Continue Reading
Ramsay Santé Optimizes Debt Structure with New TLB Reppricing

Updated Category News Views 242

Ramsay Santé Successfully Reprices Term Loans for Financial Growth Ramsay Santé recently achieved a significant milestone by repricing its €1,025 million Term Loan B4 (TLB4) and extending its €425 million Term Loan B3 (TLB3), effectively consolidating them into a new Term Loan B5. This strategic move is set to enhance their financial standing as part of their...

Continue Reading
NKGen Biotech to Present Innovative Research at Global Congress

Updated Category News Views 157

NKGen Biotech's Exciting Announcement on Upcoming Presentation NKGen Biotech Inc. (NASDAQ: NKGN), a pioneering clinical-stage biotechnology firm dedicated to developing cutting-edge autologous and allogeneic natural killer cell therapies, has recently shared some thrilling news regarding their participation in an international event. Highlighting Neurodegenerative...

Continue Reading